Huntingtin (HTT) is a large (~350 kDa) multi-domain protein encoded by the HTT gene on chromosome 4p16.3. While named for its role in Huntington's disease (HD), huntingtin is an essential protein with fundamental functions in embryonic development, neuronal physiology, and cellular homeostasis. The protein contains a polymorphic polyglutamine (polyQ) tract in its N-terminus, and expansion of this tract beyond 35-39 CAG repeats causes Huntington's disease, one of the most common neurodegenerative disorders.
Huntingtin is a fascinating protein that exemplifies both the normal functions of a large scaffold protein and the pathogenic consequences of specific genetic mutations. This ~3,144 amino acid protein is expressed ubiquitously but is particularly abundant in the brain, where it participates in numerous cellular processes essential for neuronal survival and function. This comprehensive page covers the structure, normal functions, disease mechanisms, and therapeutic strategies related to huntingtin.
{{Infobox .infobox .infobox-protein
| protein_name = Huntingtin Protein
| gene = HTT
| uniprot_id = P42857
| molecular_weight = ~350 kDa (full-length)
| localization = Cytoplasmic, nuclear, synaptic vesicles
| family = Huntingtin protein family
}}
¶ Domain Organization
Huntingtin is organized into multiple functional domains:
-
Polyglutamine (polyQ) tract (N-terminus, residues 1-60): The first exon contains a polymorphic CAG repeat encoding glutamine. Normal alleles have 10-35 repeats. Pathogenic expansions (>36 repeats) cause Huntington's disease, with earlier onset associated with longer repeats.
-
Polyproline (polyP) tract: Adjacent to the polyQ tract, this region mediates protein-protein interactions through SH3 domain binding.
-
HEAT repeat domains (residues 600-2800): Huntingtin contains 36 alpha-helical HEAT (Huntingtin, Elongation factor 3, A subunit of PP2A, Tor) repeats that form elongated superhelical structures. These repeats mediate interactions with numerous partner proteins.
-
Nuclear localization signals (NLS): Multiple NLS sequences facilitate huntingtin's shuttling between cytoplasm and nucleus.
-
Nuclear export signals (NES): Hydrophobic sequences enabling export from the nucleus.
-
Caspase cleavage sites: Multiple Asp-Glu-Val-Asp (DEVD) sequences are recognized by caspases (particularly caspase-3 and caspase-6), generating toxic fragments in HD.
Huntingtin is extensively modified:
- Phosphorylation: Over 100 phosphorylation sites identified. Key sites include S421 (neuroprotective), S116, S265, and T3.
- Acetylation: At Lys444, acetylation enhances mutant HTT clearance via autophagy.
- Sumoylation: Modification that can influence aggregation and transcriptional regulation.
- Palmitoylation: Affects membrane association and vesicular trafficking.
- Embryonic development: HTT knockout is embryonic lethal in mice, indicating essential role in development
- Cell survival: Anti-apoptotic functions through multiple mechanisms
- Cellular transport: Facilitates vesicular transport along microtubules
- Synaptic vesicle dynamics: Regulates synaptic vesicle pooling, release, and recycling
- Receptor trafficking: Controls AMPA, NMDA, and GABA receptor trafficking to the plasma membrane
- Presynaptic functions: Regulates synapsin phosphorylation and vesicle mobilization
Huntingtin interacts with numerous transcription factors:
- REST/NRSF: Sequesters REST in the cytoplasm; loss of HTT leads to REST nuclear translocation and repression of neuronal genes
- p53: Modulates p53 transcriptional activity and apoptosis
- NCoR/SMRT: Co-repressor complexes involved in neuronal gene expression
- CBP/p300: Histone acetyltransferases affected in HD
- Kinesin/dynein interactions: Serves as a scaffold for motor proteins
- Vesicle trafficking: Transport of synaptic vesicles, neurotrophic factors (BDNF), and organelles
- Mitochondrial trafficking: Coordination of mitochondrial distribution in neurons
- Selective autophagy: Interacts with autophagy receptors (p62, OPTN)
- Lysosomal function: Regulates autophagosome-lysosome fusion
- Cargo recognition: Facilitates clearance of damaged organelles and protein aggregates
- BDNF trafficking: Critical for axonal transport of brain-derived neurotrophic factor
- TrkB signaling: Modulates neurotrophin receptor activation
- Inheritance: Autosomal dominant, full penetrance
- Repeat instability: Maternal and paternal expansion can occur, particularly paternal transmission
- Anticipation: Earlier onset in successive generations
- Modifier genes: Genetic modifiers influence age of onset (e.g., DNA repair genes)
-
Transcriptional dysregulation: Mutant HTT (mHTT) sequesters transcription factors (CBP, p53, REST) in aggregates, disrupting gene expression
-
Mitochondrial dysfunction:
- Impaired mitochondrial dynamics (fusion/fission)
- Reduced respiratory chain activity
- Increased ROS production
- Disrupted calcium handling
-
Excitotoxicity:
- Enhanced NMDA receptor activity
- Impaired glutamate transport
- Calcium dysregulation
-
Protein aggregation:
- mHTT forms insoluble aggregates in nucleus and cytoplasm
- Disrupts cellular transport, transcription, and organelle function
-
Axonal transport defects:
- Impaired BDNF delivery
- Synaptic vesicle depletion
- Reduced neurotransmitter release
-
Autophagy impairment:
- Defective autophagosome formation
- Reduced clearance of damaged organelles
- Accumulation of protein aggregates
- Reduced normal HTT activity compounds toxicity
- Impaired BDNF transport
- Decreased neuroprotective signaling
- Striatal degeneration: Medium spiny neurons (MSNs) in caudate and putamen are most vulnerable
- Cortical involvement: Layer 5 pyramidal neurons show atrophy
- White matter changes: Diffusion abnormalities in HD mutation carriers
- Other regions: Thalamus, hippocampus, cerebellum affected in later stages
- Mechanism: Single-stranded DNA analogs that bind mRNA and promote RNase H degradation
- Clinical trials: Several ASOs have entered clinical trials (e.g., Tominersen, others)
- Challenges: Delivery to brain, allele specificity, timing of intervention
- shRNA/siRNA delivery: Viral vectors (AAV) expressing hairpin RNAs
- Allele-specific targeting: Exploiting SNP differences between alleles
- Gene editing: Correcting the expansion or reducing HTT expression
- Epigenetic modulation: Modifying DNA methylation or histone marks
- Small molecules: Designed to prevent or disrupt HTT aggregation
- Peptide-based inhibitors: Designed aggregation-blocking peptides
- Phosphorylation modulators: S421 phosphorylation enhancers
- Acetylation modifiers: K444 acetylation to promote clearance
- Proteostasis enhancers: Activating autophagy pathways
- BDNF augmentation: Enhancing neurotrophic support
- Metabolic support: CoQ10, NAD+ precursors, creatine
- Excitotoxicity blockers: Memantine, amantadine
- Mitochondrial protectants: Antioxidants, mitochondrial dynamics modulators
- knock-in mice: CAG repeat expansions knocked into endogenous Htt locus
- Transgenic models: Expressing full-length or fragment mHTT (R6/1, R6/2)
- Yeast artificial chromosome (YAC) mice: Large genomic fragments with mutant HTT
- Fragment models: N-terminal fragments with expanded polyQ
- Inducible models: Temporal control of mHTT expression
- HTT mutations are not typical PD risk factors
- Common pathways: mitochondrial dysfunction, protein aggregation, autophagy impairment
- Potential for shared therapeutic approaches
- HTT can influence APP processing and Aβ generation
- Shared transcriptional dysregulation mechanisms
- Common therapeutic targets in protein homeostasis
- Overlapping RNA processing abnormalities
- Shared defects in protein homeostasis
- Similar aggregate pathology
¶ Biomarkers and Outcome Measures
- Motor markers: Unified Huntington's Disease Rating Scale (UHDRS)
- Cognitive markers: Neuropsychological testing batteries
- Neuroimaging: Striatal volume, white matter integrity
- Biochemical markers: Neurofilament light chain (NfL), mutant HTT in CSF
- Genetic modifiers: Understanding what modifies age of onset
- Biomarker development: Identifying reliable progression markers
- Combination therapies: Multi-target approaches
- Premanifest intervention: Treating before symptoms emerge
The study of Huntingtin Protein (Htt) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Gusella JF, MacDonald ME. Huntington's disease: seeing the pathogenic processes through a genetic lens. Trends in Biochemical Sciences. 2006;31(9):533-540. PMID:16854264
-
The Huntington's Disease Collaborative Research Project. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72(6):971-983. PMID:8458085
-
Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annual Review of Neuroscience. 2007;30:575-621. PMID:17417937
-
Bates GP, Dorsey R, et al. Huntington disease. Nature Reviews Disease Primers. 2015;1:15005. PMID:27189881
-
Tabrizi SJ, Flower MD, Ross CA, Wild EJ. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nature Reviews Neurology. 2020;16(10):529-546. PMID:32843754
-
Saudou F, Humbert S. The biology of huntingtin. Neuron. 2016;89(5):910-926. PMID:26938440
-
DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277(5334):1990-1993. PMID:9302293
-
Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nature Reviews Neuroscience. 2005;6(12):919-930. PMID:16288287
-
Zheng S, Claborn B. The molecular biology of Huntington's disease. Disorder Markers. 2022;2022:8284522. PMID:36035060
-
Gauthier LR, Charrin BC, Borrell-Pagès M, et al. Huntingtin controls neurotrophic support and electrical activity of adenoviral brain-derived neurotrophic factor. Cell. 2004;116(2):281-297. PMID:14744441